secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001104659-26-038258
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics closes oversubscribed $30M private placement to fund APR-1051 development
--------------------------------------------------------------------------------

- Closed oversubscribed $30M private placement on March 31, 2026; proceeds for R&D and general corporate.
- Proceeds to accelerate APR-1051 development, targeting uterine serous carcinoma and platinum-resistant ovarian cancer with 50+ patients.
- Offering led by Soleus Capital; included pre-funded warrants at ~$0.807/sh and warrants at $0.683/sh, expiring Dec 2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926038258/0001104659-26-038258-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465926038258/apre-20260401x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-038258

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer